GGHC
FOLD

Gilder Gagnon Howe & Co’s Amicus Therapeutics FOLD Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,305,432
Closed -$22.8M – 419
2021
Q1 		$22.8M Buy
2,305,432
+47,681
+2% +$738K 0.12% 148
2020
Q4 		$52.1M Buy
2,257,751
+173,009
+8% +$3.54M 0.26% 101
2020
Q3 		$29.4M Sell
2,084,742
-41,769
-2% -$609K 0.18% 118
2020
Q2 		$32.1M Buy
+2,126,511
New +$25.9M 0.25% 99
2019
Q3 		– Sell
-15,000
Closed -$187K – 290
2019
Q2 		$187K Buy
+15,000
New +$190K ﹤0.01% 271
2015
Q4 		– Sell
-381,695
Closed -$5.34M – 253
2015
Q3 		$5.34M Sell
381,695
-158,829
-29% -$2.49M 0.08% 128
2015
Q2 		$7.65M Buy
+540,524
New +$6.5M 0.1% 134

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gilder Gagnon Howe & Co's FOLD Position: Q2 2021 in Review

Gilder Gagnon Howe & Co sold out of Amicus Therapeutics (FOLD) in Q2 2021, closing a stake of 2,305,432 shares — an estimated $22.8M sold.

Gilder Gagnon Howe & Co first reported a position in FOLD in Q2 2015 and held it in 7 quarters. The position peaked at $52.1M in Q4 2020. 235 funds tracked by Wall St. Rank hold FOLD as of Q2 2021.

  • Gilder Gagnon Howe & Co reported no remaining Amicus Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 2,305,432 Amicus Therapeutics shares in Q2 2021, an estimated $22.8M.
  • Gilder Gagnon Howe & Co first reported a position in Amicus Therapeutics in Q2 2015 and held it in 7 quarters.
  • Gilder Gagnon Howe & Co's Amicus Therapeutics position peaked at $52.1M in Q4 2020.
  • 235 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2021.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2021, filed 16 Aug 2021.